指导临床医生为新诊断晚期卵巢癌患者选择维持治疗的共识声明和治疗算法:一项德尔菲研究的结果
由6名意大利妇科肿瘤专家组成的委员会基于科学证据制定实践导向声明,通过改良德尔菲研究由22名专家组成的小组达成共识,提出27条基于证据和共识的声明,涵盖生物标志物使用、手术时机与结局、贝伐珠单抗适用患者选择、治疗反应定义、毒性及禁忌证、贝伐珠单抗联合PARP抑制剂协同证据,并包含两个治疗算法。
要点
- 共识涵盖生物标志物、手术时机与结局、贝伐珠单抗选择、治疗反应定义、毒性及禁忌证等。
- 提出两个治疗算法,基于手术时机与结局、铂类化疗反应及生物标志物状态选择维持治疗。
- 提出化疗反应评估评分,但其验证仍在进行中。
核心结论
- 提供共识声明和治疗算法,以指导临床医生在晚期卵巢癌一线管理中選擇适当且个体化的维持治疗。
研究设计与样本
- 由6名意大利妇科肿瘤专家组成的委员会召开会议,基于科学证据制定实践导向声明,通过改良德尔菲研究由来自意大利各地的22名专家组成的小组达成共识。
主要发现
- 提出27条基于证据和共识的声明,涵盖生物标志物(BRCA突变和同源重组缺陷存在)、手术时机与结局、贝伐珠单抗适用患者选择、治疗反应定义、毒性及禁忌证、贝伐珠单抗联合PARP抑制剂协同证据等领域。
- 包含两个治疗算法,用于根据手术时机与结局、铂类化疗反应和生物标志物状态选择维持治疗。
- 提出一个化疗反应评估评分,但其验证仍在进行中。
关键数值与推荐
- 27条基于证据和共识的声明覆盖生物标志物使用、手术时机与结局、贝伐珠单抗选择、治疗反应定义、毒性及禁忌证、贝伐珠单抗联合PARP抑制剂协同证据。
- 两个治疗算法基于手术时机与结局、铂类化疗反应及生物标志物状态选择维持治疗。
- 提出化疗反应评估评分,验证仍在进行中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 化疗反应评估评分的验证仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Standard treatment of newly diagnosed, advanced ovarian carcinoma (OC) consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently shown to significantly improve progression-free survival in the first-line setting. Some practical aspects of maintenance therapy, however, are still poorly defined. AIM OF THE STUDY: To provide guidance to clinicians in the selection of maintenance therapy for newly diagnosed, advanced ovarian carcinoma. METHODS: A board of six gynecologic oncologists with expertise in the treatment of OC in Italy convened to address issues related to the new options for maintenance treatment. Based on scientific evidences, the board produced practice-oriented statements. Consensus was reached via a modified Delphi study that involved a panel of 22 experts from across Italy. RESULTS: Twenty-seven evidence- and consensus-based statements are presented, covering the following areas of interest: use of biomarkers (BRCA mutations and presence of homologous recombination deficiency); timing and outcomes of surgery; selection of patients eligible for bevacizumab; definition of response to treatment; toxicity and contraindications; evidence of synergy of bevacizumab plus PARP inhibitor. Two treatment algorithms are also included, for selecting maintenance therapy based on timing and outcomes of surgery, response to platinum-based chemotherapy and biomarker status. A score for the assessment of response to chemotherapy is proposed, but its validation is ongoing. CONCLUSIONS: We provide here consensus statements and treatment algorithms to guide clinicians in the selection of appropriate and personalized maintenance therapy in the first-line setting of advanced OC management.
引用
- Colombo N, Gadducci A, Landoni F, et al. Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study. Gynecol Oncol. 2023. PMID: 37355448. doi:10.1016/j.ygyno.2023.05.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。